| Literature DB >> 35565886 |
Jaithri Ananthapavan1,2, Gary Sacks2, Liliana Orellana3, Josephine Marshall2, Ella Robinson2, Marj Moodie1,2, Miranda Blake2, Amy Brown4, Rob Carter1, Adrian J Cameron2.
Abstract
The supermarket environment impacts the healthiness of food purchased and consumed. Shelf tags that alert customers to healthier packaged products can improve the healthiness of overall purchases. This study assessed the potential value-for-money of implementing a three-year shelf tag intervention across all major supermarket chains in Australia. Cost-benefit analyses (CBA) and cost-utility analyses (CUA) were conducted based on results of a 12-week non-randomised controlled trial of a shelf tag intervention in seven Australian supermarkets. The change in energy density of all packaged foods purchased during the trial was used to estimate population-level changes in mean daily energy intake. A multi-state, multiple-cohort Markov model estimated the subsequent obesity-related health and healthcare cost outcomes over the lifetime of the 2019 Australian population. The CBA and CUA took societal and healthcare sector perspectives, respectively. The intervention was estimated to produce a mean reduction in population body weight of 1.09 kg. The net present value of the intervention was approximately AUD 17 billion (B). Over 98% of the intervention costs were borne by supermarkets. CUA findings were consistent with the CBA-the intervention was dominant, producing both health benefits and cost-savings. Shelf tags are likely to offer excellent value-for-money from societal and healthcare sector perspectives.Entities:
Keywords: cost–benefit analysis; cost–utility analysis; economic evaluation; healthy retail; shelf tag; supermarket
Mesh:
Year: 2022 PMID: 35565886 PMCID: PMC9103654 DOI: 10.3390/nu14091919
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Figure 1Logic pathway of intervention effect on average population weight and body mass index. Notes: BMI: body mass index; g: grams; kg: kilogram; kJ: kilojoules.
Specifications of the primary cost–benefit and cost–utility analyses.
| CBA Primary Analysis | CUA Primary Analysis | |
|---|---|---|
|
| Societal, Australian population | Healthcare system |
|
| Status quo—no shelf tag intervention | |
|
| Shelf tag intervention—3-year intervention and duration of effect | |
|
| Lifetime account of healthcare costs and health impacts | |
|
| 3% (recommended by CBA framework [ | 5% (recommended by PBAC [ |
|
| Supermarket industry, government | Government—health sector |
|
| HALYs valued using VSLY | HALYs gained |
|
| NPV/BCR | ICER: AUD per HALY gained |
|
| Univariate and multivariate sensitivity analyses (see | |
|
| Equity and distributional impacts and other considerations described (qualitatively) | |
|
| Disaggregate costs and benefits across subgroups (retailers, individuals, government, and various healthcare payers (e.g., state and federal governments, individuals and private health insurers). | Overall findings |
Notes: AUD: Australian dollar; BCR: benefit–cost ratio; CBA: cost–benefit analysis; CUA: cost–utility analysis; HALY: health-adjusted life years; HSR: Health Star Rating; ICER: incremental cost–effectiveness ratio; NPV: net present value; PBAC: Pharmaceutical Benefits Advisory Committee; VSLY: value of a statistical life year; WTP: willingness to pay; * probabilistic sensitivity analyses (PSA) incorporated into all analyses.
Description of sensitivity analyses.
| Cost–Benefit Analysis | Cost–Utility Analysis | |
|---|---|---|
|
| 0%, 5%, 7%, 10% | 0%, 3.5% |
|
| 1 year of intervention duration, 8 weeks of intervention effect (duration of the initial study) | |
|
| Only 50% of IGA stores implement the intervention, no implementation in other supermarket chains | |
|
| Remove consumer surplus benefit | No change |
|
| 30 years | No change |
|
| HALY gained: AUD 50,000; AUD 92,114; AUD 329,981 | No change |
|
| No change | Societal perspective—include implementation costs accrued by retailers. 3% discount rate. |
|
| Cost of passing legislation in each state/territory. Increased implementation of 80% in all major supermarket chain stores. Implementation and monitoring costs and intervention effect for 20 years. Consumer surplus benefit was assumed to last for 3 years. | |
Notes: AUD: Australian dollars, 2019 values; HALY: health-adjusted life year; SA: sensitivity analysis.
Cost-effectiveness results, mean (95% UI).
| Cost–Benefit Analysis | Cost–Utility Analysis | |
|---|---|---|
|
| −1.09 (−2.22; −0.21) | |
|
| −0.41 (−0.82; −0.08) | |
|
| 50,923 (11,499; 101,399) | 36,930 (7527; 70,817) |
|
| AUD 29.8 M (18.5 M; 44.1 M) | AUD 0.7 M (0.4 M; 1.1 M) |
| Government Costs | AUD 0.7 M (0.4 M; 1.1 M) | AUD 0.7 M (0.4 M; 1.1 M) |
| Supermarket Costs | AUD 29.1 M (17.8 M; 43.5 M) | N/A |
|
| AUD 16.8 B (3.9 B; 33.6 B) | N/A |
| Total Healthcare Cost-Savings | AUD 542.5 M (121.6 M; 1.1 B) | AUD 406.5 M (81.5 M; 787.4 M) |
| Consumer Surplus (Information Benefits of HSR) | AUD 139.8 M (8.5 M; 670.4 M) | N/A |
| Value of health gains | AUD 16.2 B (3.6 B; 32.2 B) | N/A |
|
| N/A | − AUD 405.6 M (−786.8 M; −80.6 M) |
|
| AUD 16.8 B (3.8 B; 33.6 B) | N/A |
|
| 591 (118; 1278) | N/A |
|
| N/A | Dominant (Dominant to Dominant) |
|
| 99.6% | 99.2% |
Notes: AUD: Australian dollars, 2019 values; B: billions; BCR: benefit–cost ratio; BMI: body mass index; CUA: cost–utility analysis; HALYs: health-adjusted life years gained; HSR: Health Star Rating; ICER: incremental cost–effectiveness ratio; m: meters; kg: kilograms; M: millions; N/A: not applicable; NPV: net present value; UI: uncertainty interval. *Negative net costs represent savings. Dominant means that the intervention produces cost-savings and health gains compared to the no intervention comparator. β ICER below AUD 50,000 per HALY gain.
Figure 2Cost-effectiveness plane for the primary cost–utility analysis.
Cost-effectiveness results, mean (95% UI).
| Stakeholder Group | Costs, Mean (95% UI) | Benefits |
|---|---|---|
|
| Total: AUD 29.1 M (17.8 M; 43.5 M) | Customer perceptions: The majority of customers exposed to healthy food retail interventions in supermarkets and grocery stores reported positive reactions to the intervention [ |
|
| AUD 0 | Healthcare costs-saving: AUD 231.7 M |
|
| AUD 0.7 M (0.4 M; 1.1 M) | Healthcare costs-saving: AUD 150.3 M |
|
| AUD 0 | Healthcare costs-saving: AUD 44.5 M |
|
| AUD 0 | Healthcare costs-saving: AUD 79.8 M |
Notes: AUD: Australian dollars, 2019 values; HSR: Health Star Rating; M: billi ons; UI: uncertainty interval. * Accrued by all businesses. Healthcare cost-savings accrued by the various stakeholders was informed by proportion of total health expenditure by governments, private health insurers and individuals as reported by the Australian Institute of Health and Welfare [69]. Note that total healthcare cost-savings from Table 3 are greater than the sum of the healthcare cost-savings across the reported stakeholders because 6.7% of healthcare costs are accrued by other non-government sources (i.e., injury compensation insurers and other sources of private income).